[HTML][HTML] Precision medicine approaches to overcome resistance to therapy in head and neck cancers
S Ortiz-Cuaran, J Bouaoud, A Karabajakian… - Frontiers in …, 2021 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
[HTML][HTML] Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
C Palumbo, M Benvenuto, C Focaccetti… - Frontiers in …, 2023 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type,
has often an aggressive course and is poorly responsive to current therapeutic approaches …
has often an aggressive course and is poorly responsive to current therapeutic approaches …
[HTML][HTML] Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer
L Lang, F Wang, Z Ding, X Zhao, R Loveless… - Journal of Experimental …, 2021 - Springer
Background Alterations in metabolism are one of the emerging hallmarks of cancer cells and
targeting dysregulated cancer metabolism provides a new approach to developing more …
targeting dysregulated cancer metabolism provides a new approach to developing more …
[HTML][HTML] Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and/or metastatic head and neck squamous cell …
Simple Summary To improve overall survival (OS), we evaluated a combination of
cetuximab and nivolumab for toxicity and efficacy in patients with incurable recurrent and/or …
cetuximab and nivolumab for toxicity and efficacy in patients with incurable recurrent and/or …
Monoclonal antibodies in oncology: a decade of novel options
V Kardile, A Kulkarni, B Nadar, T Saldanha - Cell Biochemistry and …, 2023 - Springer
Several decades of research and clinical trials have conclusively provided proof of concept
on the usefulness of monoclonal antibodies in the armamentarium against cancer. There are …
on the usefulness of monoclonal antibodies in the armamentarium against cancer. There are …
[HTML][HTML] Current aspects and future considerations of EGFR inhibition in locally advanced and recurrent metastatic squamous cell carcinoma of the head and neck
B Patel, NF Saba - Cancers, 2021 - mdpi.com
Simple Summary Squamous cell carcinoma of the head and neck (SCCHN) is a debilitating
disease that affects hundreds of thousands of individuals worldwide and has a high mortality …
disease that affects hundreds of thousands of individuals worldwide and has a high mortality …
[HTML][HTML] Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma
A Song, Y Wu, W Chu, X Yang, Z Zhu… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
MicroRNAs are major post-transcriptional regulators responsible for the development of
human cancers, including OSCC. The specific role of miR-619-5p in OSCC, however, is …
human cancers, including OSCC. The specific role of miR-619-5p in OSCC, however, is …
[HTML][HTML] Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
Hypopharyngeal squamous cell carcinoma (HPSCC) has a very poor prognosis. Local
surgery may increase survival, but is often avoided due to significant post-op co-morbidities …
surgery may increase survival, but is often avoided due to significant post-op co-morbidities …
[HTML][HTML] Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
MR Jubran, D Vilenski, E Flashner-Abramson… - Theranostics, 2022 - ncbi.nlm.nih.gov
Therapeutic strategies for advanced head and neck squamous carcinoma (HNSCC) consist
of multimodal treatment, including Epidermal Growth Factor Receptor (EGFR) inhibition …
of multimodal treatment, including Epidermal Growth Factor Receptor (EGFR) inhibition …
[HTML][HTML] Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck …
T Kurosaki, S Mitani, K Tanaka, S Suzuki… - Anti-Cancer …, 2021 - journals.lww.com
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic …
carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic …